SCHEMBL4934302

SCHEMBL4934302

O=c1[nH]c2ccc(OC(F)(F)F)cc2n1C1CCN(C2CCOCC2)CC1

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 12/20 0.67
CHRM2 P08172 5/20 0.67
CHRM4 P08173 5/20 0.67
CHRM3 P20309 4/20 0.67
CHRM5 P08912 3/20 0.67
KCNH2 Q12809 2/20 0.67
OPRM1 P35372 8/20 0.55
OPRL1 P41146 2/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
DRD2 P14416 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4636170 0.99 CHRM1 (0.66) CHRM1CHRM2CHRM4CHRM3CHRM5
SCHEMBL4637224 0.88 CHRM1 (0.67) CHRM1CHRM2CHRM4CHRM3CHRM5
SCHEMBL4635808 0.87 CHRM1 (0.63) CHRM1CHRM2CHRM4CHRM3CHRM5
Hydrochloric Acid SCHEMBL4635701 0.87 CHRM1 (0.66) CHRM1CHRM2CHRM4CHRM3CHRM5
Hydrochloric Acid SCHEMBL4636547 0.86 CHRM1 (0.62) CHRM1CHRM2CHRM4CHRM3CHRM5
SCHEMBL4939509 0.86 CHRM1 (0.74) CHRM1CHRM2CHRM4CHRM3CHRM5
SCHEMBL605786 0.85 OPRM1 (0.54) CHRM1CHRM2CHRM4CHRM3CHRM5
SCHEMBL604197 0.85 OPRM1 (0.54) CHRM1CHRM2CHRM4CHRM3CHRM5
SCHEMBL604196 0.85 OPRM1 (0.54) CHRM1CHRM2CHRM4CHRM3CHRM5
Trifluoroacetic Acid SCHEMBL4636107 0.84 CHRM1 (0.63) CHRM1CHRM2CHRM4CHRM3CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US claimed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US claimed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
WO-2007036711-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor CHRM1, CHRM2, CHRM4 CHRM1 1/4885CHRM2 2/4885CHRM4 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.